The Alkaloid #4: The Quiet Eleven Million

Eleven million American adults used psilocybin in the past year.

THE ALKALOID

Science, culture and capital — one dose at a time.

Issue #4 — April 29, 2026

THE DOSE

The Quiet Eleven Million

Somewhere in the past five years, while the legal and political world was preoccupied with what psilocybin should be, a different question was answered without anyone in particular asking it. Roughly eleven million American adults used psilocybin in the past year, according to the most recent population estimates. That is more people than live in the states of Pennsylvania or Illinois. It is more than triple the population of Los Angeles. And it has happened almost entirely without legal frameworks, medical infrastructure, or public conversation catching up to the reality.

The data come from a multisource observational study published in the Annals of Internal Medicine, drawing from five nationally representative datasets including the National Survey on Drug Use and Health, the National Poison Data System, and Monitoring the Future. The authors, led by researchers at the Colorado School of Public Health, found that lifetime psilocybin use among American adults rose from 10 percent in 2019 to 12.1 percent in 2023. In raw numbers, that is a jump from roughly 25 million people who had ever tried psilocybin to over 31 million.

The deeper finding is the demographic shape of the change. Past-year psilocybin use increased 44 percent among young adults aged 18 to 29, which most observers would have predicted. The surprise is what happened in older age brackets. Among adults 30 and over, past-year use rose by 188 percent in the same window. The cultural perception of psilocybin as a young person's substance is now several years out of date.

Researchers also found psilocybin users in 2023 were significantly more likely than nonusers to report moderate to severe anxiety, moderate to severe depression, or chronic pain. The pattern suggests something more than recreational curiosity. Substantial numbers of people are turning to psilocybin specifically because conventional treatments have not worked, and they are doing so without medical supervision because supervised access barely exists outside Oregon and Colorado.

By 2023, more American adults reported using psilocybin than cocaine, LSD, methamphetamine, or illegal opioids. Psilocybin is now the second most commonly used substance in the country behind cannabis. This did not happen because of marketing, advertising, or legal access. It happened through word of mouth, online communities, harm reduction networks, and a quiet collective decision by millions of people that they would rather try this than continue suffering.

What the data are documenting is not a trend. It is a shift in how a large segment of the American population is approaching mental health, pain, and meaning. The institutions designed to study, regulate, and care for these people are years behind the people themselves.

QUICK HITS

Poison center calls climbed dramatically. Between 2019 and 2023, psilocybin-related poison center calls rose 201 percent among adults, 317 percent among adolescents, and 723 percent among children. In 2023 alone, U.S. poison centers received over 1,100 adult calls, more than 500 involving adolescents, and nearly 300 involving children under 12. The vast majority of pediatric cases involved accidental ingestion of edible products.
Hospital data missed the surge entirely. Despite the population-level surge, official hospital data showed only three emergency department cases involving psilocybin between 2015 and 2021. The mismatch between what poison centers see and what hospitals record reflects how poorly current medical surveillance systems track psychedelic use.
Senior use is rising fast. Cannabis use among adults 65 and older has reached a new high, with seven percent of seniors reporting past-month use. The aging demographic moving into psychedelic and cannabis space changes the political calculus on access reform considerably.
A long-lost LSD fungus found. A microbiology student identified a fungus producing effects similar to LSD that researchers, including LSD's inventor Albert Hofmann, had been searching for since the compound was first synthesized. Genuine pharmaceutical development potential and a 70-year-old mystery solved.
Twelfth grade use jumped 53 percent. Past-year psilocybin use among 12th graders rose 53 percent between 2019 and 2023, reaching 2.5 percent of high school seniors. The increase is smaller than adult numbers but represents a meaningful shift in adolescent exposure.

SCIENCE DESK

Why the surveillance gap matters

The most overlooked finding in the Annals study is the discrepancy between what poison control centers observed and what hospital systems recorded. Poison center calls related to psilocybin tripled in adults and rose more than seven-fold in young children during the same period that official emergency department data showed only three psilocybin-related cases over six years. That gap is not because nothing happened. It is because the categories used to track psychedelic exposures in hospitals are fragmented, inconsistent, and were never designed to capture the kind of use pattern emerging now.

This matters for reasons beyond data quality. Public health response infrastructure, harm reduction funding, regulatory frameworks, and clinical guidelines all depend on accurate measurement of who is using what, why, and under what conditions. If the surveillance system is blind to the eleven million people now using psilocybin annually, the response will remain reactive, fragmented, and chronically underprepared.

The pediatric exposure data is particularly relevant. The 723 percent increase in poison center calls involving children under 12 is almost certainly tied to the rise of edible psilocybin products, including chocolates and gummies that look indistinguishable from candy. Cannabis edibles created a similar pediatric exposure pattern over the past decade. The lesson should be familiar by now. Packaging requirements, child-resistant containers, and clear labeling exist for a reason. Without legal frameworks, those protections do not exist for psilocybin products at all.

The research community is calling for improved tracking tools and educational outreach as more states consider regulation. The challenge is that policy infrastructure typically lags behavior by years. Eleven million people are not waiting.

MARKET WATCH

The cultural normalization documented in the Annals study has direct implications for psychedelic biotech valuations. The investment thesis underlying companies like Compass Pathways, Cybin, and AtaiBeckley has long depended on demonstrating both clinical efficacy and consumer demand. The clinical side is being addressed through FDA-cleared trials. The demand question now has its answer.

When eleven million American adults are already using psilocybin annually outside any legal framework, the addressable market for legal, supervised, and pharmaceutically regulated access is potentially enormous. That number also creates a competitive dynamic worth watching. Underground access is free or cheap. Pharmaceutical access through psilocybin clinics will likely cost hundreds to thousands of dollars per session. The market segmentation challenge is whether legal access can capture meaningful share against established underground supply chains.

State-licensed programs in Oregon and Colorado offer early data. Oregon's licensed service centers opened in summer 2023 and Colorado's program followed under Proposition 122. Both have struggled with high costs, limited insurance coverage, and slow patient throughput. The structural advantage may belong to companies that find pricing and accessibility models closer to therapeutic ketamine clinics than traditional pharmaceutical pricing.

The cannabis market remains relevant context. Federal rescheduling continues to be slow-walked. The hemp THC ban deadline looms in November. The same underlying dynamic shaping psilocybin use, where consumer behavior outpaces legal infrastructure by years, is the dynamic that built the cannabis industry into a $28 billion sector before federal law caught up. There is no obvious reason psilocybin will move differently.

THE LAST WORD

There is an important framing question buried in this data that gets lost in the policy debate. The eleven million people using psilocybin in 2026 are not, in the main, recreational users seeking novelty. They are people with anxiety, depression, chronic pain, addiction, trauma, and grief who have run out of options that work. Conventional treatments fail substantial portions of patients with these conditions, and psilocybin offers a path that growing evidence suggests is genuinely effective for many of them.

This is what makes the surveillance gap, the regulatory delay, and the political theater around psychedelic policy actually consequential. Real people are making real medical decisions for real conditions, and the systems supposed to support them are showing up years late with frameworks shaped more by political possibility than by patient need.

The eleven million number is not a warning. It is information. It is a measurement of how much suffering exists in this country, how few resources address it, and how many people are willing to take matters into their own hands when nothing else has worked. The honest response to that data is not concern about the number. It is humility about what the current system has failed to provide for the people in it.

— The Alkaloid

Sources